HEMAB THERAPEUTICS HOLDINGS Stock Price, News & Analysis

Hemab Therapeutics Holdings, Inc. Overview

Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. The company focuses on serious bleeding and thrombotic diseases and has stated a mission to discover, develop, and commercialize therapies for patients affected by these conditions. Hemab’s named programs include antibody candidates in clinical development for Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.

Hemab’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol COAG on May 1, 2026. The company completed its initial public offering after the full exercise of the underwriters’ option to purchase additional shares, with all shares in the offering sold by Hemab. For investors researching COAG stock, the company’s identity is tied to clinical-stage drug development rather than a broad commercial product base.

Core Business Focus

Hemab is building a franchise of therapeutics designed to address what the company describes as critical gaps in the treatment of coagulation disorders. Its work centers on prophylactic therapeutics for bleeding disorders, with one operating segment engaged in research and development. The company’s available profile identifies discovery, development, and potential commercialization as its main business activities.

The company’s pipeline is focused on antibody-based approaches. The programs named in company materials are:

• Sutacimig (HMB-001): a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
• HMB-002: a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.

These programs define Hemab’s current company profile. Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease are the specific disorders named in the company’s materials, and each is connected to one of Hemab’s clinical-stage candidates.

Clinical-Stage Biotechnology Profile

As a clinical-stage biotechnology company, Hemab’s public profile is linked to research, development, and clinical progress. The company’s materials describe its goal as reimagining the treatment of blood coagulation disorders to sustain life and human resilience. Its stated mission also references millions of patients worldwide suffering from serious bleeding and thrombotic diseases.

Hemab does not describe itself as a company with multiple commercial divisions. Instead, the available company description identifies one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders. That makes the status of its named clinical programs central to understanding the company.

Public Company Context

COAG represents Hemab Therapeutics Holdings, Inc. as a Nasdaq-listed biotechnology stock. The company’s IPO established public trading for its common stock under the COAG symbol. The offering materials described Hemab as the issuer of all shares sold in the IPO, which means the public-market transaction was centered on financing the company rather than selling shares held by existing stockholders.

For company research, the most relevant facts are Hemab’s clinical-stage status, its focus on blood coagulation disorders, its antibody candidates, and its Nasdaq listing. The company’s value proposition in its own materials is not framed around a marketed product line; it is framed around the development of therapies for serious bleeding and thrombotic diseases.

Key Takeaways for COAG Stock Research

• Hemab Therapeutics Holdings, Inc. trades on the Nasdaq Global Select Market under the symbol COAG.
• The company is a clinical-stage biotechnology company focused on blood coagulation disorders.
• Hemab’s stated mission is to discover, develop, and commercialize therapies for serious bleeding and thrombotic diseases.
• Sutacimig (HMB-001) is a bispecific antibody in clinical development for Glanzmann thrombasthenia and Factor VII deficiency.
• HMB-002 is a monovalent antibody in clinical development for Von Willebrand Disease.
• The company has one operating segment focused on research and development of prophylactic therapeutics for bleeding disorders.